TWI505827B - 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物 - Google Patents

治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物 Download PDF

Info

Publication number
TWI505827B
TWI505827B TW101108193A TW101108193A TWI505827B TW I505827 B TWI505827 B TW I505827B TW 101108193 A TW101108193 A TW 101108193A TW 101108193 A TW101108193 A TW 101108193A TW I505827 B TWI505827 B TW I505827B
Authority
TW
Taiwan
Prior art keywords
hyperuricemia
gout
diacerein
group
rhein
Prior art date
Application number
TW101108193A
Other languages
English (en)
Chinese (zh)
Other versions
TW201249432A (en
Inventor
Mannching Sherry Ku
I Yin Lin
Wei Shu Lu
Chih Kuang Chen
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of TW201249432A publication Critical patent/TW201249432A/zh
Application granted granted Critical
Publication of TWI505827B publication Critical patent/TWI505827B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101108193A 2011-03-11 2012-03-09 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物 TWI505827B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11

Publications (2)

Publication Number Publication Date
TW201249432A TW201249432A (en) 2012-12-16
TWI505827B true TWI505827B (zh) 2015-11-01

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101108193A TWI505827B (zh) 2011-03-11 2012-03-09 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011517A (es) * 2010-04-08 2012-11-29 Twi Biotechnology Inc El uso de diacereina como una terapia adyuvante para diabetes.
JP6012639B2 (ja) 2011-03-11 2016-10-25 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
US9744131B2 (en) 2015-07-01 2017-08-29 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
KR20180037261A (ko) * 2015-08-17 2018-04-11 티더블유아이 바이오테크놀로지 인코포레이티드 Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
WO2008051496A2 (en) * 2006-10-20 2008-05-02 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US20090123446A1 (en) * 2006-10-20 2009-05-14 Regeneron Pharmaceuticals, Inc. Use of IL-1 Antagonists to Treat Gout
TW201018461A (en) * 2008-10-28 2010-05-16 Anchen Lab Inc Pharmaceutical compositions containing diacerein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821924B2 (en) * 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
US20100150938A1 (en) 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
JP6012639B2 (ja) 2011-03-11 2016-10-25 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
WO2008051496A2 (en) * 2006-10-20 2008-05-02 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US20090123446A1 (en) * 2006-10-20 2009-05-14 Regeneron Pharmaceuticals, Inc. Use of IL-1 Antagonists to Treat Gout
TW201018461A (en) * 2008-10-28 2010-05-16 Anchen Lab Inc Pharmaceutical compositions containing diacerein

Also Published As

Publication number Publication date
US20120232044A1 (en) 2012-09-13
IL228030A0 (en) 2013-09-30
JP6012639B2 (ja) 2016-10-25
KR20140019795A (ko) 2014-02-17
RU2013145498A (ru) 2015-04-20
AU2012229443B2 (en) 2017-03-02
US8865689B2 (en) 2014-10-21
RU2603050C2 (ru) 2016-11-20
JP2014507476A (ja) 2014-03-27
TW201249432A (en) 2012-12-16
KR101567885B1 (ko) 2015-11-10
WO2012125359A1 (en) 2012-09-20
ES2634562T3 (es) 2017-09-28
CN103429236B (zh) 2016-09-21
EP2683372A1 (en) 2014-01-15
NZ614486A (en) 2014-11-28
CA2829101C (en) 2019-08-20
IL228030B (en) 2018-01-31
CA2829101A1 (en) 2012-09-20
MX2013010384A (es) 2013-10-07
EP2683372B1 (en) 2017-07-12
AU2012229443A1 (en) 2013-09-12
AR085662A1 (es) 2013-10-16
PT2683372T (pt) 2017-10-25
CN103429236A (zh) 2013-12-04
EP2683372A4 (en) 2014-08-06
MX350666B (es) 2017-09-12
BR112013022332A2 (pt) 2017-05-30

Similar Documents

Publication Publication Date Title
TWI505827B (zh) 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物
EP3038654B1 (en) New use
JP6008974B2 (ja) 痛風発赤の治療方法
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
JP2011515349A5 (enExample)
JP2019089825A (ja) 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
CN1771040B (zh) 糖尿病治疗药
TW201811372A (zh) 利用fxr促效劑之方法
CN102892760B (zh) 非醇性脂肪性肝炎的预防和/或治疗剂
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP2022526914A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
KR20220168172A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2019510777A (ja) Ｎｓａｉｄ誘発性の心血管、脳血管又は腎血管の有害事象を治療するための方法
AU782001B2 (en) Methods for treating cardiogenic shock using a nitric oxide synthase inhibitor
HK40062581A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
TW201637650A (zh) 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
JP2010501604A (ja) グルコースレベルを低下させる方法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees